Relmada Therapeutics Gears Up to Become a Publicly Traded Company

NEW YORK, May 20, 2013 /PRNewswire/ -- Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that has retained Brio Financial Group ("Brio") and GBH CPAs, PC ("GBH") as financial reporting consultant and audit firms, respectively. This important development is in line with the plan to prepare the company for a public listing. Both Brio Financial Group and GBH have extensive experience in performing these critical services, specifically for companies of Relmada's size and stage of development.

"We believe that the significant progress achieved over the last few months and the expected pipeline developments that are ahead of us during the summer largely sustain a company profile that can be supported in the public markets. The addition of Brio and GBH to the Relmada team provides us with the right expertise to comply with the financial reporting and audit requirements necessary for Relmada to become a public company" said Sergio Traversa, CEO of Relmada Therapeutics.

About Brio Financial Group

Brio Financial Group is a financial and management consulting group based in Somerset, New Jersey. The focus of the firm is to provide outsourced financial management and financial reporting support to small and middle market entities, both publicly and privately owned. The management team at Brio consists of three seasoned CFO executives as well as two CPA's with over 15 years of experience in public accounting. Currently, the team provides consulting services to over 20 private and publicly traded companies. Brio professionals have experience dealing with both domestic as well as international client bases. The professionals have represented companies on multiple exchanges.

About GBH CPAs, PC

GBH CPAs, PC (www.gbhcpas.com) is an accounting firm specializing in providing audit services for small to medium-sized public companies under SEC rules and Canadian rules and in serving closely-held, private clients. GBH is registered with the Public Company Accounting Oversight Board ("PCAOB") and the Canadian Public Accountability Board ("CPAB") and is a member of the AICPA Center for Audit Quality and the Texas Society of Certified Public Accountants. GBH was selected by INSIDE Public Accounting to the Best of the Best Firms list for 2012.

About Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical stage, private biopharmaceutical company focused on developing both novel versions of proven drugs and new molecules that potentially address high unmet medical needs in the treatment of chronic pain. The Company has a deep and diversified portfolio of four lead products at different stages of development and an early stage pipeline of an additional three products. Relmada's strategy focuses on the development of d-methadone as an innovative NMDA (N-Methyl-D-aspartate) inhibitor for Diabetic Peripheral Neuropathy (DPN), LevoCap ER, its abuse resistant, oncea-day sustained release dosage form of the opioid analgesic levophanol; MepiGel, its FDA Orphan Drug designated topical local anesthetic gel formulation of mepivacaine for Post Herpetic Neuralgia (PHN) and BuCap ER, its once-a-day oral sustained release dosage form of the opioid analgesic buprenorphine.

For more information, contact:

Visit our website at www.relmada.com or contact:

Sergio Traversa, CEO
Relmada Therapeutics Inc.

Tel: 646-801-8112

E-Mail: relmadamedia@relmada.com

SOURCE Relmada Therapeutics, Inc.